MA54953A - Composés, compositions et procédés - Google Patents
Composés, compositions et procédésInfo
- Publication number
- MA54953A MA54953A MA054953A MA54953A MA54953A MA 54953 A MA54953 A MA 54953A MA 054953 A MA054953 A MA 054953A MA 54953 A MA54953 A MA 54953A MA 54953 A MA54953 A MA 54953A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- compounds
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805263P | 2019-02-13 | 2019-02-13 | |
| US201962877232P | 2019-07-22 | 2019-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54953A true MA54953A (fr) | 2021-12-22 |
Family
ID=72043948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054953A MA54953A (fr) | 2019-02-13 | 2020-02-12 | Composés, compositions et procédés |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11306077B2 (fr) |
| EP (1) | EP3923935A4 (fr) |
| JP (2) | JP2022520236A (fr) |
| KR (1) | KR20210126036A (fr) |
| CN (1) | CN113518618A (fr) |
| AU (1) | AU2020223228A1 (fr) |
| BR (1) | BR112021015639A2 (fr) |
| CA (1) | CA3129609A1 (fr) |
| CL (1) | CL2021002104A1 (fr) |
| CO (1) | CO2021010490A2 (fr) |
| CR (1) | CR20210426A (fr) |
| IL (1) | IL285302A (fr) |
| MA (1) | MA54953A (fr) |
| MX (1) | MX2021009669A (fr) |
| PE (1) | PE20212023A1 (fr) |
| PH (1) | PH12021551923A1 (fr) |
| SA (1) | SA521430021B1 (fr) |
| SG (1) | SG11202108552QA (fr) |
| TW (1) | TWI877136B (fr) |
| WO (1) | WO2020168011A1 (fr) |
| ZA (1) | ZA202105930B (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49858A (fr) | 2017-08-09 | 2021-04-28 | Denali Therapeutics Inc | Composés, compositions et procédés |
| JP7382308B2 (ja) | 2017-09-01 | 2023-11-16 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物、及び、方法 |
| EP3723762A4 (fr) | 2017-12-13 | 2021-12-08 | Praxis Biotech LLC | Inhibiteurs de la voie de réponse intégrée au stress |
| WO2019236710A1 (fr) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibiteurs de la voie de réponse intégrée au stress |
| BR112021015853A2 (pt) | 2019-02-13 | 2021-10-05 | Ptc Therapeutics, Inc. | Compostos de tieno[3,2-b]piridin-7-amina para o tratamento de disautonomia familiar |
| EP3924050A1 (fr) | 2019-02-13 | 2021-12-22 | PTC Therapeutics, Inc. | Composés de pyrrolo[2,3-d] pyrimidine pour le traitement de la dysautonomie familiale |
| EP3924341A4 (fr) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Composés, compositions et procédés |
| CA3129609A1 (fr) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Modulateurs de facteur 2b de demarrage eucaryote |
| CN114466654A (zh) | 2019-06-12 | 2022-05-10 | 普拉西斯生物技术有限责任公司 | 整合应激反应通路调节剂 |
| US12441720B2 (en) | 2020-03-11 | 2025-10-14 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| LT4232154T (lt) | 2020-10-22 | 2025-02-10 | Evotec International Gmbh | Integruoto streso atsako kelio moduliatoriai |
| MX2023004677A (es) * | 2020-10-22 | 2023-05-24 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| CN116761803A (zh) * | 2020-10-22 | 2023-09-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| KR20230110511A (ko) | 2020-10-22 | 2023-07-24 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| US20240059662A1 (en) * | 2020-12-18 | 2024-02-22 | Denali Therapeutics Inc. | Solid forms of a compound |
| WO2024032501A1 (fr) * | 2022-08-08 | 2024-02-15 | 深圳众格生物科技有限公司 | Composé, composition pharmaceutique le comprenant et utilisation associée |
| TW202506628A (zh) | 2023-03-03 | 2025-02-16 | 日商大金工業股份有限公司 | 含氟化合物 |
| JP7633577B2 (ja) | 2023-03-03 | 2025-02-20 | ダイキン工業株式会社 | 含フッ素重合体 |
| EP4574872A4 (fr) | 2023-03-03 | 2025-12-10 | Daikin Ind Ltd | Composé contenant du fluor |
| WO2025019827A1 (fr) * | 2023-07-20 | 2025-01-23 | Denali Therapeutics Inc. | Formulation, forme posologique solide et méthodes |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| AU762345B2 (en) | 1998-10-16 | 2003-06-26 | Asubio Pharma Co., Ltd. | Aminophenoxyacetic acid derivatives as neuroprotectants |
| AR024077A1 (es) | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| US20010047100A1 (en) * | 2000-04-26 | 2001-11-29 | Kjaersgaard Hans Joergen | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
| CA2443108A1 (fr) * | 2001-04-03 | 2002-10-17 | Merck & Co. Inc. | Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| ZA200702375B (en) | 2004-09-02 | 2009-03-25 | Vertex Pharma | Quinazolines useful as modulators of ion channels |
| AU2006250987A1 (en) | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| PL1966130T3 (pl) * | 2005-12-23 | 2014-05-30 | Zealand Pharma As | Zmodyfikowane związki mimetyczne lizyny |
| AU2007309117A1 (en) | 2006-10-20 | 2008-05-02 | Arete Therapeutics, Inc. | Phenylurea compounds as soluble epoxide hydrolase inhibitors |
| ATE520687T1 (de) | 2007-06-15 | 2011-09-15 | Actelion Pharmaceuticals Ltd | 3-amino-6-(1-amino-ethyl)-tetrahydropyranderiva e |
| PL2376497T3 (pl) | 2008-12-12 | 2014-03-31 | Idorsia Pharmaceuticals Ltd | Pochodne 5-amino-2-(1-hydroksyetylo)tetrahydropiranu |
| US9421211B2 (en) | 2009-05-28 | 2016-08-23 | President And Fellows Of Harvard College | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation |
| SG10201405826RA (en) | 2009-06-17 | 2014-12-30 | Vertex Pharma | Inhibitors of influenza viruses replication |
| AR084457A1 (es) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| BR112013021537B1 (pt) | 2011-02-24 | 2021-08-10 | Nerviano Medical Sciences S.R.L. | Derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase |
| RU2612534C2 (ru) | 2011-03-10 | 2017-03-09 | Дайити Санкио Компани, Лимитед | Диспиропирролидиновые производные |
| EP4328223A3 (fr) | 2011-04-22 | 2024-11-06 | Signal Pharmaceuticals, LLC | Diaminocarboxamidepyrimidines et diaminocarbonitrilepyrimidines substituées, compositions de celles-ci et procédés de traitement à l'aide de celles-ci |
| JP2015512873A (ja) * | 2012-02-14 | 2015-04-30 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 殺線虫性のシス（ヘテロ）アリールシクロプロピルカルボキサミド誘導体 |
| CN104837820A (zh) | 2012-10-02 | 2015-08-12 | 大日本住友制药株式会社 | 咪唑衍生物 |
| US9447026B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2014144952A2 (fr) | 2013-03-15 | 2014-09-18 | Peter Walter | Modulateurs de la voie eif2 alpha |
| WO2015038778A1 (fr) | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | Activateurs substitués de l'urée-kinase eif2α |
| RS58175B1 (sr) | 2014-04-04 | 2019-03-29 | Syros Pharmaceuticals Inc | Inhibitori ciklin-zavisne kinaze 7 (cdk7) |
| JP6833677B2 (ja) | 2014-09-17 | 2021-02-24 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 二環式化合物 |
| NZ730728A (en) | 2014-11-20 | 2022-04-29 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| US10183938B2 (en) | 2014-12-16 | 2019-01-22 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors |
| JP2018509404A (ja) | 2015-02-25 | 2018-04-05 | ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ | デスアセトキシツブリシンｈおよびその類似体 |
| GB201506894D0 (en) * | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CU20170139A7 (es) | 2015-05-05 | 2018-03-13 | Bayer Pharma AG | Derivados de ciclohexano sustituido con amido |
| TW201718557A (zh) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW202506629A (zh) * | 2016-05-05 | 2025-02-16 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| CA3026983A1 (fr) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Composes chimiques |
| US20190298705A1 (en) | 2016-06-08 | 2019-10-03 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| PT3481819T (pt) | 2016-07-06 | 2022-08-12 | Acquist Llc | Compostos e a sua utilização para reduzir os níveis de ácido úrico |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| KR20190087622A (ko) | 2016-12-08 | 2019-07-24 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 질환 치료를 위한 이중 류신 지퍼 (dlk) 키나아제의 바이시클로[1.1.1]펜탄 억제제 |
| WO2018225093A1 (fr) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques utilisés comme inhibiteurs de la voie atf4 |
| ES2883701T3 (es) * | 2017-06-09 | 2021-12-09 | Bristol Myers Squibb Co | Agonistas del receptor 2 del péptido formilado de ciclopropil urea y agonistas del receptor 1 del péptido formilado |
| JP2020525513A (ja) * | 2017-07-03 | 2020-08-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 |
| US20200140383A1 (en) | 2017-07-03 | 2020-05-07 | Glaxosmithkline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| MA49858A (fr) * | 2017-08-09 | 2021-04-28 | Denali Therapeutics Inc | Composés, compositions et procédés |
| JP7382308B2 (ja) | 2017-09-01 | 2023-11-16 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物、及び、方法 |
| WO2019054430A1 (fr) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | Composé amide ayant un hétérocycle aromatique |
| WO2019090074A1 (fr) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulateurs de la voie de réponse intégrée au stress |
| CA3080964A1 (fr) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulateurs de la voie de reponse integree au stress |
| CA3080948A1 (fr) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulateurs de la voie de reponse integree au stress |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| JP7184889B2 (ja) | 2017-11-02 | 2022-12-06 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| WO2019090088A1 (fr) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulateurs de la voie de réponse intégrée au stress |
| CN112218851A (zh) | 2017-11-02 | 2021-01-12 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3723762A4 (fr) | 2017-12-13 | 2021-12-08 | Praxis Biotech LLC | Inhibiteurs de la voie de réponse intégrée au stress |
| WO2019183589A1 (fr) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulateurs du facteur 2 d'initiation eucaryote |
| WO2019193540A1 (fr) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Dérivés hétéroaryles de formule (i) utilisés en tant qu'inhibiteurs d'atf4 |
| WO2019193541A1 (fr) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de cycle aromatiques bicycliques de formule (i) utilisés en tant qu'inhibiteurs d'atf4 |
| BR112021000332A2 (pt) | 2018-07-09 | 2021-04-06 | Glaxosmithkline Intellectual Property Development Limited | Compostos químicos |
| WO2020031107A1 (fr) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques |
| TWI771621B (zh) | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| CA3129609A1 (fr) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Modulateurs de facteur 2b de demarrage eucaryote |
| EP3924341A4 (fr) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Composés, compositions et procédés |
| US20220177456A1 (en) | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR20220004105A (ko) * | 2019-04-23 | 2022-01-11 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| SG11202111970WA (en) | 2019-04-30 | 2021-11-29 | Calico Life Sciences Llc | Substituted cyclolakyls as modulators of the integrated stress pathway |
| AU2020264485A1 (en) | 2019-04-30 | 2021-12-02 | Abbvie Inc. | Substituted cycloalkyls as modulators of the integrated stress pathway |
| KR20220133252A (ko) * | 2020-01-28 | 2022-10-04 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절자 |
| US20240059662A1 (en) | 2020-12-18 | 2024-02-22 | Denali Therapeutics Inc. | Solid forms of a compound |
-
2020
- 2020-02-12 CA CA3129609A patent/CA3129609A1/fr active Pending
- 2020-02-12 PE PE2021001317A patent/PE20212023A1/es unknown
- 2020-02-12 EP EP20755645.7A patent/EP3923935A4/fr active Pending
- 2020-02-12 AU AU2020223228A patent/AU2020223228A1/en not_active Abandoned
- 2020-02-12 JP JP2021547076A patent/JP2022520236A/ja not_active Withdrawn
- 2020-02-12 WO PCT/US2020/018007 patent/WO2020168011A1/fr not_active Ceased
- 2020-02-12 CN CN202080017506.7A patent/CN113518618A/zh active Pending
- 2020-02-12 BR BR112021015639-9A patent/BR112021015639A2/pt unknown
- 2020-02-12 SG SG11202108552QA patent/SG11202108552QA/en unknown
- 2020-02-12 MX MX2021009669A patent/MX2021009669A/es unknown
- 2020-02-12 CR CR20210426A patent/CR20210426A/es unknown
- 2020-02-12 KR KR1020217027796A patent/KR20210126036A/ko active Pending
- 2020-02-12 TW TW109104414A patent/TWI877136B/zh active
- 2020-02-12 PH PH1/2021/551923A patent/PH12021551923A1/en unknown
- 2020-02-12 MA MA054953A patent/MA54953A/fr unknown
-
2021
- 2021-05-28 US US17/334,587 patent/US11306077B2/en active Active
- 2021-08-02 IL IL285302A patent/IL285302A/en unknown
- 2021-08-10 CL CL2021002104A patent/CL2021002104A1/es unknown
- 2021-08-10 CO CONC2021/0010490A patent/CO2021010490A2/es unknown
- 2021-08-10 SA SA521430021A patent/SA521430021B1/ar unknown
- 2021-08-18 ZA ZA2021/05930A patent/ZA202105930B/en unknown
-
2022
- 2022-03-23 US US17/702,718 patent/US11958840B2/en active Active
-
2024
- 2024-09-10 JP JP2024156648A patent/JP2024166311A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021551923A1 (en) | 2022-08-01 |
| TW202045164A (zh) | 2020-12-16 |
| WO2020168011A1 (fr) | 2020-08-20 |
| CL2021002104A1 (es) | 2022-04-08 |
| BR112021015639A2 (pt) | 2021-10-05 |
| EP3923935A1 (fr) | 2021-12-22 |
| JP2024166311A (ja) | 2024-11-28 |
| ZA202105930B (en) | 2025-03-26 |
| CO2021010490A2 (es) | 2021-08-30 |
| IL285302A (en) | 2021-09-30 |
| TWI877136B (zh) | 2025-03-21 |
| JP2022520236A (ja) | 2022-03-29 |
| CA3129609A1 (fr) | 2020-08-20 |
| CR20210426A (es) | 2021-09-30 |
| US20230114472A1 (en) | 2023-04-13 |
| US20210292311A1 (en) | 2021-09-23 |
| US11958840B2 (en) | 2024-04-16 |
| SA521430021B1 (ar) | 2024-08-11 |
| AU2020223228A1 (en) | 2021-08-26 |
| KR20210126036A (ko) | 2021-10-19 |
| EP3923935A4 (fr) | 2022-10-26 |
| PE20212023A1 (es) | 2021-10-18 |
| CN113518618A (zh) | 2021-10-19 |
| MX2021009669A (es) | 2021-10-13 |
| SG11202108552QA (en) | 2021-09-29 |
| US11306077B2 (en) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54953A (fr) | Composés, compositions et procédés | |
| MA54959A (fr) | Composés, compositions et procédés | |
| MA49858A (fr) | Composés, compositions et procédés | |
| EP3917927A4 (fr) | Immunomodulateurs, compositions et procédés associés | |
| EP3676297A4 (fr) | Composés, compositions et procédés | |
| MA54946A (fr) | Procédés et composés | |
| MA54875A (fr) | Compositions oligonucléotidiques et procédés associés | |
| MA56032A (fr) | Composés, compositions et procédés d'utilisation | |
| EP3316894A4 (fr) | Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés | |
| DK3924443T3 (da) | Compositions | |
| EP3494119A4 (fr) | Composés et compositions, et utilisations associées | |
| LT4084779T (lt) | 1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos | |
| MA52896A (fr) | Composés inhibiteurs de vmat2, compositions et méthodes associées | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| EP3871694A4 (fr) | Composition | |
| EP3364984A4 (fr) | Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés | |
| EP3967726A4 (fr) | Composition durcissable | |
| EP4077318A4 (fr) | Composés | |
| EP3552017A4 (fr) | Composés, compositions et méthodes | |
| EP4079787A4 (fr) | Composition durcissable | |
| EP3981256A4 (fr) | Composition | |
| EP3801021A4 (fr) | Procédés et compositions sporicides | |
| EP3953348A4 (fr) | Composés, compositions et procédés | |
| EP3941942A4 (fr) | Composition | |
| MA45795A (fr) | Composés et compositions, et utilisations associées |